|Please support this
website by purchasing via the links on the website.
Health Conditions > Diabetes > Diabeta
Diabeta, Micronase (glyburide/glibenclamide)
News & Research:
Glyburide - rxlsit.com -
"Glyburide appears to lower the blood glucose
acutely by stimulating the release of insulin from the pancreas, an effect
dependent upon functioning beta cells in the pancreatic islets"
Common Diabetes Drugs May Carry Risk, Study Suggests - WebMD, 9/26/13 -
"Both metformin (brand names include Glucophage and
Fortamet) and sulfonylureas (glyburide and glipizide) are commonly
prescribed as first-line therapies for patients and have been available
since the 1950s ... Patients who took sulfonylureas only were 58 percent
more likely to die from any cause than those who took metformin only ...
Sulfonylureas work "by increasing insulin release from the beta cells in the
pancreas," while metformin "acts by suppressing glucose production by the
Common diabetes drugs associated with increased risk of death - Science
Daily, 6/25/12 - "The drugs, glipizide, glyburide,
and glimepiride ... We have clearly demonstrated that metformin is
associated with a substantial reduction in mortality risk, and, thus, should
be the preferred first-line agent, if one has a choice between metformin and
a sulfonylurea ... Investigators found that all three sulfonylureas studied
were associated with a more than 50 percent greater risk of death compared
- Glyburide a Risk
for Diabetes Patients With Emergent PCI?: Glyburide Increases Risk in
Patients With Diabetes Mellitus After Emergent Percutaneous Intervention for
Myocardial Infarction – A Nationwide Study - Medscape, 11/28/11 -
"The adjusted Cox models showed an increased risk
for cardiovascular mortality with glyburide (hazard ratio [HR], 2.91; 95%
confidence interval [CI] 1.26-6.72; P = .012) compared with metformin. The
risk for cardiovascular mortality and nonfatal MI (HR, 2.69; CI, 1.21-6.00;
P = .016) and the risk for all-cause mortality (HR, 2.46; CI, 1.11-5.47; P =
.027) were also increased in patients receiving glyburide"
PERISCOPE Analysis Highlights TZD Lipid Effects - Medscape, 1/10/11 -
"In that randomized comparison of the
thiazolidinedione (TZD) vs glimepiride(Amaryl, Sanofi-Aventis) in patients
with diabetes , those taking the TZD saw significantly less coronary
disease progression as assessed with intravascular ultrasound (IVUS) over 18
months compared with those taking the other drug, a sulfonylurea. They also
benefited with steeper declines in fasting insulin and blood glucose levels,
glycated hemoglobin (HbA1C), C-reactive protein (CRP), and triglycerides as
well as improved HDL-cholesterol levels ... the post hoc analysis "ties
nicely" with the 2006 CHICAGOstudy, in which elevations in HDL were the most
important predictor of reduced progression of carotid intima-media
Pioglitazone vs glimepiride: Differential effects on vascular endothelial
function in patients with type 2 diabetes - Atherosclerosis. 2008 Dec 6
- "In patients with type 2 diabetes already on
metformin, addition of pioglitazone as compared to glimepiride, improved
endothelial function despite similar glycemic control. The improvement in
endothelial function was mainly due to a reduction in insulin resistance"
Compared - WebMD, 12/6/06 -
"Avandia had the lowest treatment failure rate --
15% -- compared with 21% for Glucophage and 34% for Micronase"
Long-term Safety of Pioglitazone vs Glyburide for Type 2 Diabetes -
Medscape, 12/1/06 - "Patients with type 2 diabetes
mellitus achieve glycemic control safely and effectively with both
pioglitazone and glyburide treatment; however, the results of this study
suggest that long-term treatment with pioglitazone is superior to glyburide
with respect to tolerability. Overall, pioglitazone treatment resulted in
sustained glycemic control, fewer patient withdrawals due to lack of
efficacy or hypoglycemia, and fewer cardiac events compared with glyburide"
Metformin-Glibenclamide Combination Is More Effective Than Monotherapy In
Type 2 Diabetes - Doctor's Guide, 4/24/03
Glyburide/Metformin Combination Effective For Type 2 Diabetes Inadequately
Controlled By Sulphonylurea - Doctor's Guide, 2/3/02
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
- N Engl J Med. 2006 Dec 4- "Kaplan-Meier analysis
showed a cumulative incidence of monotherapy failure at 5 years of 15% with
rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a
risk reduction of 32% for rosiglitazone, as compared with metformin, and
63%, as compared with glyburide (P<0.001 for both comparisons). The
difference in the durability of the treatment effect was greater between
rosiglitazone and glyburide than between rosiglitazone and metformin.
Glyburide was associated with a lower risk of cardiovascular events
(including congestive heart failure) than was rosiglitazone (P<0.05), and
the risk associated with metformin was similar to that with rosiglitazone.
Rosiglitazone was associated with more weight gain and edema than either
metformin or glyburide but with fewer gastrointestinal events than metformin
and with less hypoglycemia than glyburide"
Effect of metformin and sulfonylurea on C-reactive protein level in
well-controlled type 2 diabetics with metabolic syndrome - Endocrine
2003 Apr;20(3):215-8 -
was significantly lower in patients using
metformin for blood glucose control compared with those using
glibenclamide, 5.56 and 8.3 mg/L, respectively ... The data showed that
metformin decreases the level of circulating CRP, a marker of inflammation,
more than glibenclamide"
QualityCounts.com Anti-aging Newsletter
Netvibes basic (free)